Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
355 hedge funds and large institutions have $7.12B invested in Intra-Cellular Therapies Inc. in 2024 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 133 increasing their positions, 130 reducing their positions, and 62 closing their positions.
86% more call options, than puts
Call options by funds: $27.3M | Put options by funds: $14.7M
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
8% more capital invested
Capital invested by funds: $6.62B → $7.12B (+$501M)
2% more repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 130
6% less funds holding
Funds holding: 376 → 355 (-21)
31% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$139M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$94.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$49.8M |
| 4 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
+$30.4M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$34.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$32.6M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$30.5M |
| 4 |
Millennium Management
New York
|
-$29.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29M |
ITCI Hedge Fund Activity: Q3 2024 in Review
355 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2024, worth a combined $7.12B — up 7.6% from $6.62B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of ITCI and 43 opened new positions — a net loss of 19 holders — while 130 trimmed existing stakes and 133 added.
The largest buyer was JP Morgan Chase, adding an estimated $139M. The largest seller was Alyeska Investment Group, cutting an estimated $34.8M.
- 355 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2024, down from 376 in Q2 2024.
- Funds reported $7.12B of Intra-Cellular Therapies Inc. stock for Q3 2024, up 7.6% quarter-over-quarter.
- 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2024 and 62 closed out, a net change of -19 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2024 was JP Morgan Chase, an estimated $139M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2024 was Alyeska Investment Group, an estimated $34.8M sold.
Based on aggregated 13F filings for Q3 2024.